TROG Cancer Research said its NINJA prostate cancer trial has finished recruitment, enrolling 472 men across Australia and New Zealand.
The study is testing two shorter stereotactic body radiotherapy schedules plus androgen deprivation therapy, aiming to replace traditional courses that can take up to seven weeks of daily treatment.
TROG said the trial could cut radiation from 20-40 sessions to 5-14 sessions if the shorter schedules prove effective.
Professor Jarad Martin said the trial is now moving into follow-up and interpretation, with early safety and MRI planning data due at the ASTRO annual meeting in Boston.
The trial is being run with ANZUP Cancer Trials Group, marking a key milestone in efforts to make prostate cancer treatment more efficient.
The NINJA trial cut prostate cancer radiation to just five sessions. When will this breakthrough become the new standard of care?
More radiation in fewer visits sounds convenient, but what are the hidden long-term side effects doctors are still watching for?
NINJA Trial Completes Recruitment of 472 Patients: Paving the Way for Shorter, Safer Prostate Cancer Radiotherapy by 2031
Overview
The NINJA trial has reached a major milestone with the successful completion of recruitment, enrolling 472 men with intermediate- or high-risk, non-metastatic prostate cancer across Australia and New Zealand. This marks the end of a rigorous recruitment phase and the start of a crucial new chapter. The trial is designed to test if shorter, more targeted schedules of stereotactic body radiotherapy (SBRT), combined with androgen deprivation therapy, can safely reduce the number of treatment sessions from the traditional 20–40 down to as few as 5–14. This could lead to more convenient and effective prostate cancer treatment for patients.